These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Rituximab Improves Subclinical Temporal Dispersion of Distal Compound Muscle Action Potential in Anti-MAG/SGPG Neuropathy Associated with Waldenström Macroglobulinemia: A Case Report. Kodaira M; Yamamoto K Case Rep Neurol; 2013 Jan; 5(1):34-9. PubMed ID: 23525653 [TBL] [Abstract][Full Text] [Related]
13. Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody. Kawagashira Y; Koike H; Ohyama K; Hashimoto R; Iijima M; Adachi H; Katsuno M; Chapman M; Lunn M; Sobue G J Neurol Sci; 2015 Jan; 348(1-2):67-73. PubMed ID: 25467141 [TBL] [Abstract][Full Text] [Related]
14. Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy. Briani C; Visentin A; Salvalaggio A; Cacciavillani M; Trentin L Eur J Neurol; 2019 Feb; 26(2):371-375. PubMed ID: 30315672 [TBL] [Abstract][Full Text] [Related]
15. Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia. Weiss MD; Dalakas MC; Lauter CJ; Willison HJ; Quarles RH J Neuroimmunol; 1999 Mar; 95(1-2):174-84. PubMed ID: 10229128 [TBL] [Abstract][Full Text] [Related]